Sharekhan has come with pre-earning report on Orchid Chemicals' Q4FY07. It expects the company is likely to post net profit of Rs 25.7 crore versus Rs 19.4 crore, a strong growth of 32.4% and net sales at Rs 242.2 crore compared to Rs 239.8 crore, up 1%.

Sharekhan expects Orchid Chemicals' revenues to grow by a meagre 1% in Q4FY2007, as the company has had no major launches in the US market during the quarter. The US market is the main growth driver for the company. However, with the flu season having set in the USA, we expect the contributions from the other antibiotics like Cefozitin and Cefazolin (where Orchid Chemicals has already captured a dominant share of the market) to improve. An improving product mix, with a higher share of formulations,  is expected to improve the OPM by 190 basis points yoy to 30.7%. Orchid Chemicals' net profit growth on a year-on-year basis is likely to be strong at 32.4% to Rs25.7 crore due to the relatively lower base of Q4FY2006.